RxDoctor Payments Data

Amanda Baker

Nurse Practitioner · Chester, VANPI 1669106332

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.6% of the total across 370 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 36.0% of the total. Among nurse practitioner clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,090in general payments, 2019–2025

Across 370 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$519
  • Ardelyx, Inc.$473
  • Janssen Scientific Affairs, LLC$250
  • plus $2K from 22 others

What the payments were for

  • Consulting fees$6007%
  • Food & beverage$7,41092%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,090 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib35$308,982
CreonLipase/Protease/Amylase91$264,029
Humira(Cf) PenAdalimumab25$248,683
XifaxanRifaximin26$78,756
LinzessLinaclotide90$76,855
Humira PenAdalimumab11$74,838
ZenpepLipase/Protease/Amylase18$59,556
IbsrelaTenapanor Hcl14$24,133
VoqueznaVonoprazan Fumarate15$13,354
TrulancePlecanatide21$12,469
Mesalamine37$11,995
ClenpiqSod Picosulf/Mag Ox/Citric Ac42$7,083
Ursodiol29$6,057
Sucralfate117$4,714
Dexlansoprazole DrDexlansoprazole39$4,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Creon, Linzess$2,912$649,867216 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,050$91,22647 claims
Aimmune Therapeutics, Inc.Zenpep$53$59,55618 claims
Ardelyx, Inc.Ibsrela$473$24,13314 claims
Phathom Pharmaceuticals, Inc.Voquezna$210$13,35415 claims
Ferring Pharmaceuticals Inc.Clenpiq$124$7,08342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Chester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →